Solid Biosciences to Participate at the Truist Securities BioPharma Symposium

Rhea-AI Summary

Solid Biosciences (Nasdaq: SLDB), a company focused on developing precision genetic medicines for neuromuscular and cardiac diseases, has announced its participation in an upcoming industry event. Chief Medical Officer Gabriel Brooks, M.D. will be part of a Genetic Medicine Panel at the Truist Securities BioPharma Symposium on November 7, 2024, at 1:45 p.m. ET in New York. Institutional investors can arrange meetings with management through their Truist representatives.

AI-generated analysis. Not financial advice.

News Market Reaction – SLDB

-3.66%

1 alert

-3.66% News Effect

On the day this news was published, SLDB declined 3.66%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

CHARLESTOWN, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that Gabriel Brooks, M.D., Chief Medical Officer, will participate in a Genetic Medicine Panel at the Truist Securities BioPharma Symposium on Thursday, November 7, 2024, at 1:45 p.m. ET in New York.

Institutional investors interested in meeting with management during the conference may reach out to their Truist representatives.

About Solid Biosciences
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy (Duchenne), SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia (CPVT), AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy, and additional assets for the treatment of fatal cardiac diseases. Solid is advancing its diverse pipeline across rare neuromuscular and cardiac diseases, bringing together experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted, Solid’s mandate is to improve the daily lives of patients living with these devastating diseases. For more information, please visit www.solidbio.com.

Solid Biosciences Investor Contact:
Nicole Anderson
Director, Investor Relations and Corporate Communications
Solid Biosciences Inc.
investors@solidbio.com

Media Contact:
Glenn Silver
FINN Partners
glenn.silver@finnpartners.com

FAQ

When is Solid Biosciences (SLDB) participating in the Truist Securities BioPharma Symposium?

Solid Biosciences will participate in the Truist Securities BioPharma Symposium on Thursday, November 7, 2024, at 1:45 p.m. ET in New York.

Who will represent Solid Biosciences (SLDB) at the Truist Securities BioPharma Symposium?

Dr. Gabriel Brooks, Chief Medical Officer of Solid Biosciences, will represent the company on the Genetic Medicine Panel.

What type of medicines does Solid Biosciences (SLDB) develop?

Solid Biosciences develops precision genetic medicines focused on neuromuscular and cardiac diseases.

How can investors meet with Solid Biosciences (SLDB) management at the Truist Symposium?

Institutional investors interested in meeting with management can arrange meetings through their Truist representatives.